AIM:To explore the mechanism of BLJZF in the treatment of abnormal lipid metabolism based on network pharmacology, molecular docking and in vivo animal experiments. METHODS:TCMSP database, Swiss Target Prediction database, STITCH database and literature search were used to collect and query the chemical composition information of BLJZF and the corresponding target of drug chemical composition. Disease targets of lipid abnormalities were collected through GeneCards and OMIM databases. Metascape database was used to analyze the gene ontology function and the Kyoto Encyclopedia gene and genome pathway enrichment of common intersection targets. Cytoscape software was used to construct the correlation network diagram of components and targets, so as to select major components and targets for molecular docking study. The hyperlipidemia model was induced by high fat diet, and the control group, model group, positive group and BLJZF group were set up. The serum lipid index contents of triglyceride (TG), total cholesterol (TC), low lipoprotein cholesterol (LDL-C) and high lipoprotein cholesterol (HDL-C) were detected after continuous administration for 4 weeks. The contents of oxidative stress index were detected: alanine aminotransferase (ALT) and aspartate aminotransferase (AST). The contents of superoxide dismutase (SOD) and malondialdehyde (MDA) were detected by ELISA. Hematoxylin-eosin (HE) staining was used to detect the pathological changes of liver tissue. RESULTS:A total of 25 components and 315 corresponding targets of BLJZF were obtained, 1729 targets of lipid abnormalities and 116 common targets of BLJZF, among which the core targets were AKT1, TNF, IL1β, CASP3, etc. GO and KEGG enrichment analysis suggested that BLJZF may play a role through the lipid and atherosclerotic pathway, PI3K-Akt, AGE-RAGE in diabetic complications and other signaling pathways. Molecular docking showed that most of the core targets had high binding activity with the active ingredients. Animal experiments showed that compared with model group, TC, TG, LDL-C, ALT, AST and MDA in BLJZF group were significantly decreased, HDL-C and SOD were significantly increased, and the degree of liver fat deformation was reduced.CONCLUSION: BLJZF has a therapeutic effect on lipid abnormalities. It can treat lipid metabolism abnormalities through multi-component, multi-target and multi-pathway, and provide reference for subsequent drug research on BLJZF.